# OnCo record paper-keynote-826-nejm-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-826-nejm-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-826-nejm-2021" ;
  schema:name "KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer"@en ;
  schema:description "Adding pembrolizumab to first-line chemotherapy, with or without bevacizumab, lengthened survival in advanced cervical cancer, the first improvement in the disease since bevacizumab was added seven years earlier."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-826-nejm-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2112435>, <https://pubmed.ncbi.nlm.nih.gov/34534429/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2112435> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Colombo N, Dubot C, Lorusso D, et al." ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-826/> ;
  onco:journals <https://onco.cc/journals/nejm/> .